secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001816590-22-000117
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways: Q3 net loss $18.4M ($0.43/share); Phase 3 program on track for 2022 start
--------------------------------------------------------------------------------

- Net loss of $18.4M in Q3 2022 vs. $15.8M in Q3 2021; cash $173.1M as of Sept 30, 2022.
- Phase 3 pivotal program for COMP360 in treatment-resistant depression on track to start in 2022.
- Phase 2b trial data published in The New England Journal of Medicine.
- Phase 2 trials ongoing in anorexia nervosa and PTSD; investigator-led study in autism launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659022000117/0001816590-22-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659022000117/cmps-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001816590-22-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer